Log in to your Inderes Free account to see all free content on this page.
Initiator Pharma
7.25
SEK
-2.03 %
INIT
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-2.03%
+0.69%
-7.64%
-27.5%
-21.54%
-21.88%
-10.49%
+6.72%
+61.62%
www.initiatorpharma.com/en
Initiator Pharma is a biotechnology company. Today, the main focus is to develop drug candidates to be used in treatment of erectile dysfunction in men. The company currently has pharmaceuticals in clinical stage testing for patients that do not respond on PDE5i pharmaceuticals. Initiator Pharma was created as a spin-off from Saniona and is today based in Åbyhøj.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
INIT
Daily low / high price
7.25 / 7.4
SEK
Market cap
407.15M SEK
Turnover
9.48K SEK
Volume
1.3K
Financial calendar
Annual report
28.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Linc AB | 18.0 % | 18.0 % |
| Adrigo Asset Management | 6.5 % | 6.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
INITIATOR PHARMA: Q3 2024 REPORT
Completion of capital increase in Initiator Pharma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio